The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
Authors:
- Maj-Britt JensenMJMaj-Britt Jensen
- Bent EjlertsenBEBent Ejlertsen
- Karsten D. BjerreKBKarsten D. Bjerre
- Martin LarsenMLMartin Larsen
- Hanne B. HansenHHHanne B. Hansen
- Peer ChristiansenPCPeer Christiansen
- Henning T. MouridsenHMHenning T. Mouridsen
- 1 January 2008
- journal article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 47 (4) , 506-524
Abstract
Introduction. Since 30 years, DBCG (Danish Breast Cancer Cooperative Group) has maintained a clinical database allowing the conduct of quality control studies, of randomised trials, examination of the epidemiology of breast cancer and of prognostic and predictive factors. Material and methods. The original database included patients with invasive breast cancer, but has later been expanded to patients with in situ breast cancer and hereditary breast and ovarian cancer families. Results. The multidisciplinary cooperative group has provided successive treatment guidelines and 70% of the 77284 registered patients have been enrolled and received treatment according to these guidelines. The standard treatments and the randomised trials included in the DBCG programmes are all briefly described. Among high-risk patients 48% have participated in randomised trials, and the results of these trials have largely been implemented in the next generation of treatment guidelines. Records within the clinical database of archival tumour tissue have established a basis for translational research and epidemiologic research has been enabled through linkage to other healthcare registries. Discussion. The joint conception of the multidisciplinary breast cancer group and a clinical database has provided improvements in the management of breast cancer patients and has enabled recruitment of patients onto randomised trials.Keywords
This publication has 32 references indexed in Scilit:
- Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)Acta Oncologica, 2008
- Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocolActa Oncologica, 2008
- Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experienceActa Oncologica, 2008
- Post-mastectomy radiotherapy in Denmark: From 2D to 3D treatment planning guidelines of The Danish Breast Cancer Cooperative GroupActa Oncologica, 2008
- Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancerActa Oncologica, 2008
- Recurrence pattern and prognosis in low-risk breast cancer patients – Data from the DBCG 89-A programmeActa Oncologica, 2008
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trialEuropean Journal of Cancer, 1999
- Adjuvant Therapy of Premenopausal and Menopausal High-Risk Breast Cancer Patients: Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-BActa Oncologica, 1988